Arvinas

Yahoo Finance • 12 days ago

Arvinas Employees Give Back During Company-wide Impact Day

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across C... Full story

Yahoo Finance • 17 days ago

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpowe... Full story

Yahoo Finance • 18 days ago

Arvinas Q1 Earnings Call Highlights

Arvinas logo Key Points Interested in Arvinas, Inc.? Here are five stocks we like better. VEPPANU’s FDA approval was the quarter’s biggest milestone, with CEO Randy Teel calling it the first approval of a heterobifunctional PROTAC degrad... Full story

Yahoo Finance • 18 days ago

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu. Veppan... Full story

Yahoo Finance • 19 days ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS])... Full story

Yahoo Finance • 25 days ago

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quar... Full story

Yahoo Finance • 29 days ago

Pfizer, Arvinas breast cancer therapy approved by the FDA

[US Food and Drug Administration (FDA)] The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Arvinas (ARVN [https://seekingalph... Full story

Yahoo Finance • 29 days ago

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce selection of a... Full story

Yahoo Finance • 3 months ago

Arvinas Q4 2025 Earnings Preview

* Arvinas (ARVN [https://seekingalpha.com/symbol/ARVN]) is scheduled to announce Q4 earnings results on Tuesday, February 24th, before market open. The consensus EPS Estimate is -$0.57 [https://seekingalpha.com/symbol/ARVN/earnings/estim... Full story

Yahoo Finance • 4 months ago

Indian textile maker Welspun's profit nearly wiped out on US tariff-led slowdown

Feb 12 (Reuters) - Indian textile maker Welspun Living, which exports to global retailers including Walmart and Tesco, posted a slump in ‌its quarterly profit on Thursday, as a U.S. tariff-triggered slowdown ‌in exports squeezed its margin... Full story

Yahoo Finance • 4 months ago

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas... Full story

Yahoo Finance • 6 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 –... Full story

Yahoo Finance • 6 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D... Full story

Yahoo Finance • 6 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepd... Full story

Yahoo Finance • 7 months ago

Arvinas outlines plan for $100M share buyback and targets sub-$75M quarterly run rate amid pipeline expansion

Earnings Call Insights: Arvinas, Inc. (ARVN) Q3 2025 MANAGEMENT VIEW * John Houston, Chairperson, CEO & President, stated that the third quarter marked "a dynamic and productive period for Arvinas marked by meaningful progress across b... Full story

Yahoo Finance • 7 months ago

Arvinas GAAP EPS of -$0.48, revenue of $41.9M

* Arvinas press release [https://seekingalpha.com/pr/20293952-arvinas-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (ARVN [https://seekingalpha.com/symbol/ARVN]): Q3 GAAP EPS of -$0.48. * Revenue of $41.9M... Full story

Yahoo Finance • 7 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of ARV-806 from other G12D t... Full story

Yahoo Finance • 7 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-8... Full story

Yahoo Finance • 8 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestr... Full story

Yahoo Finance • 8 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials – – After 14 days of... Full story